PL4010344T3 - Pochodne tienopirymidyny jako inhibitory acc i ich zastosowanie - Google Patents

Pochodne tienopirymidyny jako inhibitory acc i ich zastosowanie

Info

Publication number
PL4010344T3
PL4010344T3 PL20760689.8T PL20760689T PL4010344T3 PL 4010344 T3 PL4010344 T3 PL 4010344T3 PL 20760689 T PL20760689 T PL 20760689T PL 4010344 T3 PL4010344 T3 PL 4010344T3
Authority
PL
Poland
Prior art keywords
acc inhibitors
thienopyrimidine derivatives
thienopyrimidine
derivatives
acc
Prior art date
Application number
PL20760689.8T
Other languages
English (en)
Inventor
Jamie G. BATES
Ana Z. GONZALEZ BUENROSTRO
Hongyan Guo
Xiaochun Han
Brian J. Kirby
Yurong Lai
Michael L. Mitchell
Gregg M. SCHWARZWALDER
James G. Taylor
Ting Wang
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL4010344T3 publication Critical patent/PL4010344T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20760689.8T 2019-08-09 2020-08-06 Pochodne tienopirymidyny jako inhibitory acc i ich zastosowanie PL4010344T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885038P 2019-08-09 2019-08-09
PCT/US2020/045192 WO2021030142A1 (en) 2019-08-09 2020-08-06 Thienopyrimidine derivatives as acc inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
PL4010344T3 true PL4010344T3 (pl) 2025-03-03

Family

ID=72179238

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20760689.8T PL4010344T3 (pl) 2019-08-09 2020-08-06 Pochodne tienopirymidyny jako inhibitory acc i ich zastosowanie

Country Status (12)

Country Link
US (1) US11352371B2 (pl)
EP (2) EP4010344B1 (pl)
JP (1) JP7394961B2 (pl)
KR (1) KR102826192B1 (pl)
CN (1) CN114206884B (pl)
AR (1) AR119594A1 (pl)
AU (1) AU2020327926B2 (pl)
CA (1) CA3147913A1 (pl)
ES (1) ES2994667T3 (pl)
PL (1) PL4010344T3 (pl)
TW (1) TWI777214B (pl)
WO (1) WO2021030142A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702041PA (en) 2015-07-06 2017-04-27 Gilead Sciences Inc Cot modulators and methods of use thereof
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CN115397511A (zh) 2020-03-30 2022-11-25 吉利德科学公司 Cot抑制剂化合物(s)-6-(((1-(双环[1.1.1]戊-1-基)-1h-1,2,3-三唑-4-基)2-甲基-1-氧代-1,2-二氢异喹啉-5-基)甲基)))氨基8-氯-(新戊基氨基)喹啉-3-甲腈的固体形式
US11845737B2 (en) 2020-04-02 2023-12-19 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療nash之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療fxr誘發之搔癢之il-31調節劑

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
US20070276050A1 (en) 2006-02-27 2007-11-29 Gilead Sciences, Inc. Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
RS57157B1 (sr) 2011-11-11 2018-07-31 Gilead Apollo Llc Acc inhibitori i njihove primene
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
EP2822592B1 (en) 2012-03-08 2018-08-15 Ludwig Institute for Cancer Research Limited Tgf- 1 specific antibodies and methods and uses thereof
JP6417403B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ, エルエルシー Acc阻害剤及びその使用
EP2994139B1 (en) 2013-05-10 2019-04-10 Gilead Apollo, LLC Acc inhibitors and uses thereof
BR112015028173A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
EP2994138A4 (en) 2013-05-10 2016-12-28 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
JP2016529892A (ja) 2013-08-01 2016-09-29 ユニベルシテ カソリク デ ロウバイン 抗garpタンパク質及びその使用
EA201892625A1 (ru) 2015-01-09 2019-07-31 Джилид Аполло, Ллс КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
KR20180082558A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 에스테르 acc 억제제 및 그의 용도
MX2018006287A (es) 2015-11-25 2018-09-07 Gilead Apollo Llc Inhibidores de acc de triazol y usos de los mismos.
AU2016361412A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Pyrazole ACC inhibitors and uses thereof
ES2943235T3 (es) 2015-11-25 2023-06-12 Gilead Apollo Llc Composiciones fungicidas que contienen derivados de 2,4-dioxo-1,4-dihidrotieno[2,3-d]pirimidina
CN108699078A (zh) 2016-03-02 2018-10-23 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
WO2018129329A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
EP3571205B1 (en) 2017-01-22 2023-08-30 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
ES2963841T3 (es) 2017-03-03 2024-04-02 Gilead Sciences Inc Procesos para preparar inhibidores de ACC y formas sólidas del mismo
WO2018161008A1 (en) 2017-03-03 2018-09-07 Gilead Apollo, Llc Processes for the preparation of fungicidal compounds
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
JP7067725B2 (ja) * 2017-07-17 2022-05-16 ナンジン ルイジエ ファーマテック カンパニー, リミテッド Acc阻害剤としての新規な化合物およびそれらの使用
EP3691648A1 (en) 2017-10-06 2020-08-12 Gilead Sciences, Inc. Combination therapy comprising an acc inhibitor
WO2019072478A1 (en) 2017-10-10 2019-04-18 Galderma Research & Development SPECIFIC ACETYL-COA CARBOXYLASE INHIBITORS FOR USE IN THE TREATMENT AND / OR PREVENTION OF ACNE
WO2019113123A1 (en) 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof

Also Published As

Publication number Publication date
CN114206884A (zh) 2022-03-18
JP7394961B2 (ja) 2023-12-08
EP4010344C0 (en) 2024-10-02
EP4010344B1 (en) 2024-10-02
EP4010344A1 (en) 2022-06-15
TWI777214B (zh) 2022-09-11
CN114206884B (zh) 2024-07-12
TW202120512A (zh) 2021-06-01
KR102826192B1 (ko) 2025-06-27
WO2021030142A1 (en) 2021-02-18
AU2020327926A1 (en) 2022-02-17
AR119594A1 (es) 2021-12-29
US20210053990A1 (en) 2021-02-25
US11352371B2 (en) 2022-06-07
ES2994667T3 (en) 2025-01-29
CA3147913A1 (en) 2021-02-18
AU2020327926B2 (en) 2023-04-13
JP2022544199A (ja) 2022-10-17
KR20220044782A (ko) 2022-04-11
EP4545535A1 (en) 2025-04-30

Similar Documents

Publication Publication Date Title
PL4010344T3 (pl) Pochodne tienopirymidyny jako inhibitory acc i ich zastosowanie
IL272557A (en) Sulfonylureas and sulfonythioureas as NLRP3 inhibitors
EP3658557A4 (en) TYK2 INHIBITORS AND USES THEREOF
IL258636A (en) Acc inhibitors and uses thereof
HUE053175T2 (hu) ACC-gátló észterek és azok alkalmazása
EP3344624B8 (en) Tyk2 inhibitors and uses thereof
EP3268369A4 (en) Anti-alphavbeta1 integrin inhibitors and methods of use
EP3262049A4 (en) Tyk2 inhibitors and uses thereof
SG11201704521SA (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors
EP3331530A4 (en) Mthfd2 inhibitors and uses thereof
EP3681499A4 (en) CONNECTIONS AS RAS INHIBITORS AND THEIR USE
IL275195A (en) History of pyrrole as ACC inhibitors
IL274425A (en) Pyrrolopyrazine derivatives as alpha five integrin inhibitors
IL267829B (en) History of new amino-imidazopyridines as Janus kinase inhibitors and their pharmaceutical use
PL3362450T3 (pl) N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej
PT3725791T (pt) Sal que serve como inibidor de akt e seu cristal
EP3284746A4 (en) Preparation and use of kinase inhibitor
EP3596081A4 (en) PYRROLOTRIAZINE DERIVATIVES USED AS A KINASE INHIBITOR
AU2016205137B2 (en) Furoquinolinediones as inhibitors of TDP2
EP3672597A4 (en) ARF6 INHIBITORS AND RELATED PROCEDURES
HK40075742B (en) Thienopyrimidine derivatives as acc inhibitors and uses thereof
HK40023881A (en) Novel compounds and their uses as acc inhibitors
HK40102998A (zh) 新的抑制剂
HK40029719A (en) Pyrrole derivatives as acc inhibitors
HK1259986A1 (en) Acc inhibitors and uses thereof